Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01750983 · ClinicalTrials.gov registry record · Phase 1
Ipilimumab and Lenalidomide in Advanced Cancer
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 101
- Enrollment target
NCT01750983: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT01750983 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 101 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01750983, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 101 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest tolerable dose of the combination of Yervoy® (ipilimumab) with Revlimid® (lenalidomide) that can be given to patients with advanced cancer. The safety of these drugs will also be studied. Ipilimumab is designed to increase the immune system's ability to fight cancer. Lenalidomide is designed to change the body's immune system. It may also interfere with the development of tiny blood vessels that help support tumor growth. This may decrease the growth of cancer cells.
Interventions
- DRUG Ipilimumab
- DRUG Lenalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2013-03 |
| Est. Completion | 2019-02-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01750983
The ClinicalTrials.gov registry entry for NCT01750983 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ipilimumab is the first listed.
NCT01750983 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01750983 about?
NCT01750983 is a clinical study titled "Ipilimumab and Lenalidomide in Advanced Cancer". The goal of this clinical research study is to find the highest tolerable dose of the combination of Yervoy® (ipilimumab) with Revlimid® (lenalidomide) that can be given to patients with advanced cancer. The safety of these drugs will also be studied. Ipilimumab is designed to increase the immune s...
What is the current status of trial NCT01750983?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 101 participants. The study started on 2013-03. Estimated completion is 2019-02-21.
What interventions are being tested in trial NCT01750983?
The interventions under investigation include: Ipilimumab (DRUG), Lenalidomide (DRUG).
Who is sponsoring clinical trial NCT01750983?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.